TX-MAVENIR
12.4.2022 09:02:15 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced the collaboration with Aspire Technology (Aspire), a specialized Network Solutions developer and System Integrator, to accelerate the market availability of O-RAN split 7.2 compliant Remote Radiohead Units (RRUs) leveraging Aspire’s Open Networks Lab in Europe.
Communication Service Providers (CSPs) demand for integrated high performing Open Radio Access Network (Open RAN) solutions based on Mavenir O-RAN compliant cloud-native Centralized Unit (CU) and Distributed Unit (DU) RAN software stacks is growing fast, fueled by modernization and coverage expansion projects, as well as private networks and indoor projects.
The number of O-RAN compliant RRUs from partners globally is also growing with sophisticated products across the different radio technologies, including Massive MIMO (mMIMO) and millimeter Wave (mmWave).
Mavenir and Aspire will be leveraging Aspire’s Open Networks Lab in Dublin for third-party RRU integration and testing. Furthermore, RRU vendors will be able to engage directly with Aspire and fast-track the integration and testing of new O-RAN compliant radios and frequency variants with Mavenir CU/DU software.
This collaboration will benefit not only RRU vendors, but also CSPs by expanding the offering of innovative and high-performing solutions supporting a wide number of use cases.
“This partnership greatly enhances the capacity to integrate and test RRUs with Mavenir’s CU/CU for 4G and 5G,” said Puneet Sethi, SVP/GM RAN Business for Mavenir. “Open RAN has accelerated to a point that we need to continuously innovate to be ahead of demand, including go-to-market models. Our RRU partners want to get their newest products available for deployment, and CSPs want to take full advantage of a fast-paced ecosystem minimizing integration and testing effort. We are continuously expanding our partner eco-systems for RRU integration to respond to the evolving market needs with specialized high-quality services and fast turnaround.”
Declan Friel, CTO, Aspire said; “We are delighted to extend our relationship with Mavenir. Aspire’s heritage in software engineering and testing of complex radio products carried over into Open RAN, combined with global CSP experience through design, optimization and support of live networks, uniquely positions us to accelerate the availability of new ORAN compliant solutions for wide market adoption. As a European-based independent company, and with our Open Networks Lab in Ireland today supporting a number of global clients and partners, our focus has been to accelerate the ORAN ecosystem development and to support CSPs. This will allow them to fully realize the benefits of Telco Cloud, Service Management & Orchestration and Open RAN, in terms of flexibility, performance and cost.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Aspire:
Aspire Technology is a leading Specialized System Integrator with a long history and experience in fixed and mobile networks, and Open RAN since its early days. Aspire’s clients are spread around the Globe and benefit from their advanced services and software automation solutions. The Aspire Open RAN Lab enables technology partners and communications service providers to fasttrack development, integration, benchmarking, testing and deployment of Open RAN based networks and solutions. Aspire has been actively contributing to acceleration of time to market, reduction of deployment cost and improvement of multivendor interoperability and network performance. www.aspiretechnology.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005063/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom